Opinion Voices | Contributor: Focus on the real causes of the shortage in hormone treatments by Jennifer Weiss-Wolf and Suzanne Gilberg
AI generated summary, Read the full article for complete information.
The article explains that the nationwide shortage of estradiol hormone patches for menopausal women is not due to a surge in demand but stems from structural problems in the U.S. pharmacy benefit manager (PBM) system, where a few vertically integrated insurance‑pharmacy conglomerates (CVS Caremark, Express Scripts, OptumRx) control most drug coverage and logistics, giving little incentive to keep low‑margin generic products like estradiol patches consistently stocked and instead favoring higher‑priced alternatives; the piece also notes that prescription rates for hormone therapy have actually remained low, debunks media narratives blaming women, and offers practical short‑term coping strategies (alternative formulations, online or compounding pharmacies, calling ahead) while urging systemic reforms to break the PBM-driven supply constraints.
Read more: https://www.latimes.com/opinion/story/2026-04-20/estradiol-patch-shortage-drug-supply
#FDA #CVSCaremark #ExpressScripts #OptumRx #CVSHealth #Cigna #UnitedHealthGroup #FTC #
AI generated summary, Read the full article for complete information.
